TG Therapeutics Inc
TGTX
Company Profile
Business description
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Contact
3020 Carrington Mill boulevard
Suite 475
MorrisvilleNC27560
USAT: +1 212 554-4484
E: ir@tgtxinc.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
319
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,577.80 | 21.60 | -0.25% |
CAC 40 | 7,490.28 | 37.86 | 0.51% |
DAX 40 | 20,317.10 | 12.84 | -0.06% |
Dow JONES (US) | 42,635.20 | 106.84 | 0.25% |
FTSE 100 | 8,319.69 | 68.66 | 0.83% |
HKSE | 19,240.89 | 38.95 | -0.20% |
NASDAQ | 19,478.88 | 10.80 | -0.06% |
Nikkei 225 | 39,605.09 | 375.97 | -0.94% |
NZX 50 Index | 12,943.74 | 99.37 | -0.76% |
S&P 500 | 5,918.25 | 9.22 | 0.16% |
S&P/ASX 200 | 8,329.20 | 19.90 | -0.24% |
SSE Composite Index | 3,211.39 | 18.77 | -0.58% |